secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001437749-23-000695
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KemPharm appoints Richard Pascoe as CEO; Travis Mickle resigns as CEO and President
--------------------------------------------------------------------------------

- Richard W. Pascoe appointed CEO effective Jan 6, 2023; steps down as Executive Chairman.
- Travis C. Mickle resigns as CEO (immediate) and as President and board member (at 2023 annual meeting).
- Pascoe's base salary increased to $592,000, target bonus 55%, granted option for 700,000 shares.
- Mickle receives severance (18 months base salary, COBRA, pro-rata bonus), accelerated option vesting, and consulting agreement ($40k/month + 547,945 performance RSUs).
- Matthew R. Plooster appointed Chairman of the Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774923000695/0001437749-23-000695-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774923000695/kmph20230108_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-000695

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer